Skip to main content

Advertisement

Table 3 Time-dependent associations between leisure-time physical activity and overall mortality, breast cancer mortality, and recurrence-free survival in postmenopausal breast cancer survivors

From: Pre- to postdiagnosis leisure-time physical activity and prognosis in postmenopausal breast cancer survivors

Physical activity Number Events Overall mortality, HR (95% CI) Events Breast cancer mortality, HR (95% CI) Events Recurrence-free survival, HR (95% CI)
Pre- and postdiagnosis physical activitya,b Predx/postdx Predx/postdx   Predx/postdx   Predx/postdx  
 No activity 693/818 76/115 1.00 (ref.) 43/64 1.00 (ref.) 115/157 1.00 (ref.)
 Low activity 692/504 73/46 0.94 (0.74–1.19) 43/24 0.94 (0.68–1.29) 115/92 1.18 (0.98–1.43)
 Sufficient activity 657/720 58/46 0.73 (0.57–0.93) 29/27 0.64 (0.46–0.89) 99/80 0.82 (0.68–0.99)
Prediagnosis physical activityc
 No activity 677 73 1.00 (ref.) 41 1.00 (ref.) 112 1.00 (ref.)
 Low activity 676 73 1.07 (0.77–1.49) 43 1.18 (0.76–1.83) 112 1.05 (0.80–1.38)
 Sufficient activity 647 58 0.97 (0.68–1.38) 29 0.90 (0.55–1.46) 97 1.04 (0.79–1.37)
Postdiagnosis physical activityd in insufficiently active women prediagnosis
 No activity 662 91 1.00 (ref.) 53 1.00 (ref.) 121 1.00 (ref.)
 Low activity 359 37 0.71 (0.48–1.06) 18 0.65 (0.37–1.16) 69 1.14 (0.84–1.55)
 Sufficient activity 345 20 0.43 (0.26–0.72) 14 0.48 (0.25–0.91) 36 0.59 (0.40–0.86)
Postdiagnosis physical activityd in sufficiently active women prediagnosis
 No activity 91 23 1.00 (ref.) 10 1.00 (ref.) 34 1.00 (ref.)
 Low activity 37 9 0.38 (0.16–0.88) 6 0.69 (0.18–2.56) 20 0.75 (0.41–1.38)
 Sufficient activity 20 26 0.57 (0.30–1.08) 13 0.59 (0.22–1.64) 44 0.65 (0.39–1.09)
  1. aLeisure-time physical activity in MET-h/week was modelled as a time-dependent variable
  2. bAnalyses were adjusted for age at diagnosis, tumour size, nodal status, grade, ER/PR status, mode of detection, and menopausal hormone use at diagnosis, and were stratified by study centre and age at diagnosis in 5-year categories
  3. cAnalyses were adjusted for age at diagnosis, tumour size, nodal status, grade, ER/PR status, mode of detection, menopausal hormone use at diagnosis, chemotherapy, and hormone therapy, and were stratified by study centre and age at diagnosis in 5-year categories
  4. dAnalyses were adjusted for age at diagnosis, tumour size, nodal status, grade, ER/PR status, mode of detection, menopausal hormone use at diagnosis, and recurrences between diagnosis and follow-up, and were stratified by study centre and age at diagnosis in 5-year categories